Authors: Roisin Conneely
Preclinical results from TauRx Therapeutics Ltd (Aberdeen, Scotland) have indicated that LMTM, the active agent in its LMTX® drug originally developed for Alzheimer’s disease (AD) treatment, may also be beneficial as a Parkinson’s disease (PD) medication.Restricted Content / Members Only
Restricted Content / Members Only